Introduction
============

Depression is a common chronic neurological disease. It has the characteristics of high prevalence, easy recurrence, disability, low rate of visiting and low treatment rate. It has become the fifth most serious disease affecting human health ([@b1-etm-0-0-7311],[@b2-etm-0-0-7311]). The occurrence of depression is the result of a combination of multiple factors, including heredity, personality, endocrine, living environment and disease. It is currently widely believed that the reduction in levels of neurotransmitters (dopamine and serotonin) and neurotrophic factors (neuropeptide Y) is closely related to the occurrence of depression ([@b3-etm-0-0-7311]--[@b5-etm-0-0-7311]). Therefore, it has been found that the purpose of alleviating or treating depression can be achieved by increasing the levels of neurotransmitters and neurotrophic factors. Resveratrol is a polyphenolic compound that is ubiquitous in plants. It has been found in modern pharmacological studies to have multiple biological functions such as anti-inflammatory, anti-oxidation, antitumor, anti-thrombosis and anti-aging ([@b6-etm-0-0-7311]--[@b10-etm-0-0-7311]). Our early study found that resveratrol has antidepressant effects. This study analyzed its anti-depressant effects and possible mechanisms to provide a new approach to the treatment of depression.

Materials and methods
=====================

### Experimental materials

A total of 50 SPF grade C57BL/6 mice (female, 6--8 weeks old 20 g) were purchased from Shanghai Slac Laboratory Animal Co., Ltd. (Shanghai, China); resveratrol was purchased from Sigma (USA); mouse dopamine (DA), serotonin (5-HT), brain-derived nerve growth factor (BDNF) and ELISA test kit were purchased from BioAssay Systems LLC (Hayward, CA, USA); Neuropeptide (NPY) and actin monoclonal antibodies were purchased from Santa Cruz, Biotechnology, Inc. (cat. nos. sc-133080 and sc-8432; Dallas, TX, USA); actin monoclonal antibody was purchased from Hangzhou Huaan Biological Co., Ltd. (Hangzhou, China); HRP-labled goat anti-mouse secondary antibody was purchased from Beijing Zhongshan Jinqiao Biological Co., Ltd. (cat. no. ZDR-5307; Beijing, China); RIPA tissue lysate was purchased from Beyotime Biotechnology Co., Ltd. (Nantong, China); chemiluminescence kit was purchased from Hangzhou Fude Biological Technology Co., Ltd. (Hangzhou, China); M200 full-band microplate reader was purchased from Tecan Group, Ltd. (Mannedorf, Switzerland).

### Construction and treatment of depression models

A model of depression was established using social isolation combined with chronic unpredictable stress. All modeled mice were housed individually and randomized alternating stress treatment was performed once a day for 21 days. The stressors were as follows: i) fasting for 24 h; ii) water deprivation for 24 h; iii) tilting squirrel cage for 30° for 24 h; iv) clipping 1 cm of the root of mouse tail for 1 min; v) restraint with 9.5×3 cm fixator for 2 h; vi) continuously soaking in 17°C cold water for 3 min; vii) continuously soaking in 40°C hot water for 3 min and viii) day alternates with night. Each stimulus was not used continuously. After 21 days of stimulation, the mice were randomly divided into the model group, the low-dose group, the medium-dose group, and the high-dose group, with 10 mice in each group, and 10 mice of the same age were selected as controls. On the 11th day after stimulation, the low, medium and high dose groups were intraperitoneally injected with resveratrol 10, 20 and 30 mg/kg, respectively. Both the control and model groups were intraperitoneally injected with an equal volume of physiological saline once a day. After 21 days of continuous treatment, the neurobehavioral changes of each group were analyzed by forced swimming test, tail suspension experiment and sucrose consumption test.

The study was approved by the Ethics Committee of The Second Affiliated Hospital of Xinxiang Medical University (Xinxiang, China).

### Suspension experiment

The experiment was carried out in a plexiglass black box. The distal end of the mouse tail was fixed on a crossbar 30 cm from the ground. The head was facing down, and inverted status was maintained. After 6 min, it was adapted for 2 min, and then the immobility time was recorded. This result mainly reflected the degree of acquired helplessness in mice.

### Forced swimming experiment

Two hours after receiving the drug treatment, the mice were placed in a glass cylinder of 30 cm in diameter and 25 cm in height, with a water depth of 15 cm; The water temperature was maintained at 24°C, and the mice were forced to soak for 6 min. Judging criteria: All mice showed only the head exposed horizontally, floating, and the limbs were still. The immobility time was recorded 4 min after soaking.

### Sucrose consumption test

Each group of mice was fasted and water-deprived for 24 h, then 100 ml 30 mmol/l sucrose solution and 100 ml purified water were returned to the squirrel cage at 10:00 a.m. the next day. After the mice were allowed to drink for 1 h, the consumption of sucrose solution and water was measured. The sucrose partiality was then calculated according to the following formula. Sucrose partiality (%) = sucrose consumption/total liquid volume × 100%.

### Analysis of DA, 5-HT and BDNF levels by ELISA

After 24 h of the last administration, the mice were sacrificed. Brain tissue was taken, and 100 mg was weighed. Physiological saline (200 µl) was added, and the brain tissue was homogenized by a homogenizer, then centrifuged at 12,000 × g and 4°C for 10 min. The supernatant was taken, the levels of DA, 5-HT and BDNF were detected according to the manufacturer\'s instructions of ELISA.

### Western blot analysis of NPY protein expression levels

The mice were sacrificed 24 h after the last administration; brain tissue was taken, and 100 mg was weighed. Tissue lysate (200 µl) was added, and homogenized by homogenizer; allowed to stand on ice for 30 min, and centrifuged at 12,000 × g for 30 min at 4°C. Loading buffer 5X (50 µl, 60 mM Tris-HCl pH6.8, 2% SDS, 0.1% bromophenol blue, 25% glycerol; 14 mM β-mercaptoethanol) was added to the supernatant, boiled for 20 min in a metal bath, then SDS-PAGE was performed. After electrophoresis, the gel transferred to PVDF membrane, blocked with 5% skim milk powder for 1 h, and then incubated overnight with the primary antibody diluted with 5% skim milk powder (dilution, 1:1,000) at 4°C; then washed with PBST 3 times the next day, 5 min each time; after incubated with HRP-labeled goat anti-mouse secondary antibody diluted with 5% skim milk powder (dilution, 1:2,000) for 2 h at room temperature, wash 3 times with PBST, 5 min after each time, the chemiluminescence substract was applied to the PVDF membrane to develop color, and actin was used as an internal reference. Image J software (National Institute of Mental Health) was used to perform quantitative analysis.

### Statistical analysis

All data were analyzed by SPSS 17.0 statistical software (SPSS, Inc., Chicago, IL, USA). The measurement data were expressed by mean ± standard deviation (mean ± SD), and the measurement data were compared by Chi-square test. ANOVA was used for comparison of multiple groups with LSD test. P\<0.05 indicated that the difference was statistically significant.

Results
=======

### Comparison of behavioral indicators after treatment in each group of mice

Compared with the control group, the immobility time of the mice in the model group was significantly prolonged (P\<0.05) in the tail suspension and forced swimming experiment, while the consumption of syrup water was significantly decreased at 24 h, with a statistical difference (P\<0.05). Compared with the model group, the immobility time of the tail suspension experiment and the forced swimming experiment in the low-dose group was significantly shortened, while the 24-h sucrose consumption was significantly increased, and the difference was statistically significant (P\<0.05). Compared with the low-dose group, the immobility time of the suspension experiment and forced swimming experiment in the middle dose group was significantly reduced, while the 24 h syrup consumption was significantly increased, the difference was statistically significant (P\<0.05). Compared with the middle dose group, the immobility time of the tail suspension experiment and forced swimming experiment in the high dose group was significantly reduced, while the 24-h sucrose consumption was significantly increased, and the difference was statistically significant (P\<0.05) ([Table I](#tI-etm-0-0-7311){ref-type="table"}).

### Comparison of DA, 5-HT and BDNF levels in each group of mice after treatment

We further analyzed the effects of resveratrol on neurotransmitter levels in the mice brain tissue. The ELISA results showed that the levels of DA, 5-HT and BDNF in the brain tissue of the model group were significantly downregulated compared with the control group, and the difference was statistically significant (P\<0.05). After treatment with low-dose resveratrol, the levels of DA, 5-HT and BDNF in brain tissue were significantly higher than those in the model group, and the difference was statistically significant (P\<0.05). Compared with the low-dose group, the levels of DA, 5-HT and BDNF in the brain tissue of mice treated with medium dose of resveratrol were significantly increased (P\<0.05). Compared with the middle dose group, the levels of DA, 5-HT and BDNF in the brain of the high dose group were significantly increased, and the difference was statistically significant (P\<0.05) ([Table II](#tII-etm-0-0-7311){ref-type="table"}).

### Comparison of NPY levels in brain tissue of each group of mice

The expression levels of total NPY in the brain tissue of each group of mice were analyzed by western blot analysis. The results are shown in [Fig. 1](#f1-etm-0-0-7311){ref-type="fig"}. Compared with the control group, the NPY levels of the model group were significantly downregulated, and the difference was statistically significant (P\<0.05). After treatment with resveratrol, the level of NPY in the brain tissue of mice increased gradually, and in a dose-dependent manner. The comparison between the levels of NPY in the brain tissue of the low-dose, medium-dose and high-dose groups were significantly different (P\<0.05).

Discussion
==========

With the gradual increase of social and work pressure, depression, a chronic neurological disease, seriously threatens human cognition. Its incidence is increasing year by year. Epidemiological analysis shows that the incidence of different depression in young individuals is more significant and has become a social problem ([@b11-etm-0-0-7311]). Therefore, screening for highly effective and low-toxic drugs is a prerequisite for the treatment of depression. Our previous *in vitro* studies showed that after treatment of neurons with resveratrol, the level of dopamine was significantly increased. The study showed that the levels of DA, 5-HT and BDNF in patients with depression were significantly reduced, which is one of the main causes of depression. Therefore, we speculated whether resveratrol has the effect of relieving depression.

DA and 5-HT are monoamine neurotransmitters in the brain. In the pathogenesis of depression, the DA and 5-HT hypotheses are recognized. Studies also showed that the level of DA and 5-HT decreased in the hypothalamic tissue of patients with depression, indicating that depression is closely related to the low function of DA and 5-HT ([@b12-etm-0-0-7311],[@b13-etm-0-0-7311]). The levels of DA and 5-HT in the brain tissue of the mouse model of depression established in this study were significantly lower than those in normal mice, indicating that DA and 5-HT play an important role in the pathogenesis of depression. After treatment with resveratrol, the levels of DA and 5-HT increased gradually and in a dose-dependent manner. This result suggests that resveratrol may have the effect of treating depression. BDNF is a member of the neurotrophic factor family, which has the effect of promoting proliferation and differentiation of neurons, promoting neuronal survival and development, altering neuronal morphology in the brain, increasing synaptic terminal density, and promoting dendritic and axon growth ([@b14-etm-0-0-7311]). NPY is a known neuroendocrine polypeptide that plays an important regulatory role in neuronal excitability ([@b15-etm-0-0-7311]). The current study indicated that BDNF levels and brain NPY were significantly decreased in patients with depression. This result is consistent with the results obtained in the mouse model of this study. After treatment with resveratrol, the level of BDNY increased with the increase of resveratrol concentration, indicating that resveratrol may increase the activity of neurons by increasing brain-derived neurotrophic factor, thus achieving anti-depressant effect.

Behavioral analysis of mice showed that the behavior of depression in mice after resveratrol treatment was significantly relieved, indicating that resveratrol has a role in alleviating depression. Early studies on resveratrol have shown that they have important biological functions such as anti-inflammatory, antitumor and anti-aging. In addition, this study revealed a new anti-depressant biological function of resveratrol, which expanded the clinical use of resveratrol.

In summary, resveratrol can significantly increase the levels of DA, 5-HT, BDNF and NPY in the brain to achieve the effect of treating depression.
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###### 

Comparison of behavioral indicators after treatment in each group of mice.

  Groups        Tail suspension experiment(s)                                                                              Forced swimming experiment(s)                                                                              Sucrose consumption experiment(s)
  ------------- ---------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------
  Control       89.32±12.21                                                                                                79.33±14.20                                                                                                21.43±6.17
  Model         271.43±20.19^[a](#tfn1-etm-0-0-7311){ref-type="table-fn"}^                                                 194.74±21.09^[a](#tfn1-etm-0-0-7311){ref-type="table-fn"}^                                                 8.43±3.18^[a](#tfn1-etm-0-0-7311){ref-type="table-fn"}^
  Low-dose      221.33±17.17^[b](#tfn2-etm-0-0-7311){ref-type="table-fn"}^                                                 170.32±18.39^[b](#tfn2-etm-0-0-7311){ref-type="table-fn"}^                                                 17.11±4.21^[b](#tfn2-etm-0-0-7311){ref-type="table-fn"}^
  Medium-dose   174.21±14.12^[b](#tfn2-etm-0-0-7311){ref-type="table-fn"},[c](#tfn3-etm-0-0-7311){ref-type="table-fn"}^    141.30±16.33^[b](#tfn2-etm-0-0-7311){ref-type="table-fn"},[c](#tfn3-etm-0-0-7311){ref-type="table-fn"}^    14.20±3.99^[b](#tfn2-etm-0-0-7311){ref-type="table-fn"},[c](#tfn3-etm-0-0-7311){ref-type="table-fn"}^
  High-dose     130.39±15.18^[b](#tfn2-etm-0-0-7311){ref-type="table-fn"}--[d](#tfn4-etm-0-0-7311){ref-type="table-fn"}^   129.43±16.01^[b](#tfn2-etm-0-0-7311){ref-type="table-fn"}--[d](#tfn4-etm-0-0-7311){ref-type="table-fn"}^   11.98±3.02^[b](#tfn2-etm-0-0-7311){ref-type="table-fn"}--[d](#tfn4-etm-0-0-7311){ref-type="table-fn"}^

P\<0.05 compared with the control group

P\<0.05 compared with the model group

P\<0.05 compared with the low-dose group

P\<0.05 compared with the medium-dose group.

###### 

Comparison of DA, 5-HT and BDNF levels in each group of mice after treatment.

  Groups        DA(ng/g)                                                                                                   5-HT(ng/g)                                                                                                 BDNF(ng/g)
  ------------- ---------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------
  Control       654.39±30.19                                                                                               719.25±43.12                                                                                               21.43±6.17
  Model         198.25±21.44^[a](#tfn5-etm-0-0-7311){ref-type="table-fn"}^                                                 300.18±21.44^[a](#tfn5-etm-0-0-7311){ref-type="table-fn"}^                                                 8.43±3.18^[a](#tfn5-etm-0-0-7311){ref-type="table-fn"}^
  Low-dose      298.33±23.56^[b](#tfn6-etm-0-0-7311){ref-type="table-fn"}^                                                 381.24±25.44^[b](#tfn6-etm-0-0-7311){ref-type="table-fn"}^                                                 17.11±4.21^[b](#tfn6-etm-0-0-7311){ref-type="table-fn"}^
  Medium-dose   357.19±28.14^[b](#tfn6-etm-0-0-7311){ref-type="table-fn"},[c](#tfn7-etm-0-0-7311){ref-type="table-fn"}^    430.29±28.10^[b](#tfn6-etm-0-0-7311){ref-type="table-fn"},[c](#tfn7-etm-0-0-7311){ref-type="table-fn"}^    14.20±3.99^[b](#tfn6-etm-0-0-7311){ref-type="table-fn"},[c](#tfn7-etm-0-0-7311){ref-type="table-fn"}^
  High-dose     490.99±30.23^[b](#tfn6-etm-0-0-7311){ref-type="table-fn"}--[d](#tfn8-etm-0-0-7311){ref-type="table-fn"}^   551.33±32.55^[b](#tfn6-etm-0-0-7311){ref-type="table-fn"}--[d](#tfn8-etm-0-0-7311){ref-type="table-fn"}^   11.98±3.02^[b](#tfn6-etm-0-0-7311){ref-type="table-fn"}--[d](#tfn8-etm-0-0-7311){ref-type="table-fn"}^

P\<0.05 compared with the control group

P\<0.05 compared with the model group.

P\<0.05 compared with the low-dose group

P\<0.05 compared with the medium-dose group.
